Rhythm Biosciences Limited announce it has submitted its initial documentation required for Therapeutic Goods Administration approval in Australia for ColoSTAT. ColoSTAT is aimed to be a globally marketed, low-cost, simple blood test for the early detection of colorectal cancer for mass-market screening. For Rhythm, the TGA submission process will require two key steps, consisting of filingboth the Manufacturers Evidence documentation and filing for an Australian Register of Therapeutic Goods listing. The ARTG listing will contain further documentation such as the product technical files, clinical evaluation reports and the like.